Date: 2017-08-11
Type of information: Collaboration agreement
Compound: gene and cell therapy manufacturing
Company: Oxford Biomedica (UK) Cell and Gene Therapy Catapult (UK) Stratophase (UK) Synthace (UK)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism: gene therapy/cell therapy
Disease:
Details:
- • On August 11, 2017, Oxford BioMedica has announced it has agreed, as lead partner, to enter into a collaboration agreement with a consortium of partners, including the Cell and Gene Therapy Catapult, Stratophase and Synthace.
- The agreement is a two-year £2 million collaboration project focused on gene and cell therapy manufacturing, co-funded by the UK’s innovation agency, Innovate UK.
- The aim of the collaboration is to explore and apply novel advanced technologies to further evolve OXB’s proprietary suspension LentiVector® platform to deliver even higher quality vectors for both clinical and commercial use. The project aims to shorten the time-to-clinic and time-to-market as well as to improve the cost and access of bringing novel gene and cell therapies to patients.
- Each partner in the collaboration holds proprietary technology and know-how that can be used to develop an innovative approach to viral vector manufacturing. The aims of this project are closely aligned with the current government national priorities to make the UK a global hub for manufacturing advanced therapies, which will benefit economic growth and create and retain more highly skilled employment.
- Oxford BioMedica is a gene and cell therapy group. The company has recently signed an agreement with Novartis for the commercial and clinical supply of lentiviral vectors used to generate its CAR-T cell therapy CTL019 . Oxford BioMedica has already an MIA (IMP) licence for Investigational Medicinal Products (IMPs) manufacture. In August 2017, the UK Medicines and Healthcare products Regulatory Agency has also granted a Manufacturer/Importer License (MIA), from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) to manufacture and distribute lentiviral vector material for commercial supply.
- The Cell and Gene Therapy Catapult works with Innovate UK. This independent centre of excellence is focused on advancing the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 120 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world.
- Stratophase is a specialist biotech services company specialised in the adaptive control and optimisation of bioreactor environments using its patented Ranger® optical sensing technology. Synthace is developing Antha, a language and software platform specifically for biology. Antha is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment.
-
Financial terms:
Latest news:
Is general: Yes
